目的:观察瑞舒伐他汀联合常规治疗急性脑梗死(ACI)的疗效及对患者血清血管抑制因子(VS-2)、可溶性细胞黏附因子-1(s ICAM-1)和基质金属蛋白酶2(MMp2)水平的影响。方法:ACI住院患者136例随机分为对照组和观察组各68例。对照组患者予常规治疗,观察组在对照组基础上加用瑞舒伐他汀片,两组疗程均为15 d。评价两组患者疗效与药品不良反应发生率,比较两组患者治疗前后血清VS-2、s ICAM-1、MMp2水平变化。结果:观察组有效率为92.65%,明显高于对照组的77.94%(P<0.05)。两组轻型、中型和重型患者治疗后VS-2、s ICAM-1和MMp2均较前明显降低(P<0.05),且观察组各型患者血清VS-2、s ICAM-1和MMp2水平明显低于对照组相同亚组(P<0.05);两组不同梗死灶亚组治疗后血清VS-2、s ICAM-1和MMp2均较治疗前明显降低(P<0.05),且观察组不同梗死灶亚组的各项指标水平明显低于对照组相同亚组(P<0.05)。两组药品不良反应发生率比较,差异无统计学意义(P>0.05)。结论:瑞舒伐他汀治疗ACI效果较好,可降低患者血清VS-2、s ICAM-1和MMp2水平,值得临床推广使用。 OBJECTIVE: To observe the curative effect of rosuvastatin combined with routine treatment of acute cerebral infarction (ACI) and its effect on the expression of vascular endothelial cell adhesion molecule-1 (s ICAM-1) and matrix metalloproteinase 2 (MMP2 ) Level of influence. Methods: 136 cases of ACI inpatients were randomly divided into control group and observation group of 68 cases. Patients in the control group were treated routinely, and rosuvastatin tablets were added to the observation group on the basis of the control group. The course of treatment was 15 days in both groups. The curative effect and adverse drug reaction rate of the two groups were evaluated. The changes of serum VS-2, s ICAM-1 and MMp2 in two groups were compared before and after treatment. Results: The effective rate of the observation group was 92.65%, which was significantly higher than that of the control group (77.94%, P <0.05). The levels of VS-2, s ICAM-1 and MMp2 in both light, medium and heavy groups were significantly lower than those before (P <0.05), and the levels of VS-2, s ICAM-1 and MMp2 (P <0.05). The serum levels of VS-2, s ICAM-1 and MMp2 in two groups of different infarction subgroups were significantly lower than those before treatment (P <0.05) Each sub-group of indicators of the level was significantly lower than the control group the same subgroup (P <0.05). There was no significant difference between the two groups in the incidence of adverse drug reactions (P> 0.05). Conclusion: Rosuvastatin is effective in the treatment of ACI, which can reduce the serum levels of VS-2, s ICAM-1 and MMp2 in patients and is worthy of clinical promotion.